Understanding EP-NEC: Through Diagnosis, Treatment, and Support

Exploring the role of targeted radiopharmaceutical treatment in NETs

Neuroendocrine tumours (NETs) – Shared decision-making. Part 2: Individualising treatment decisions

Neuroendocrine tumours (NETs) – Shared decision-making. Part 1: Patient journey

Short-stature conditions, including SPIGFD

Regional differences in NET: Treatment and future developments

Regional differences in NET: Epidemiology, diagnosis, and referral strategies

Short stature: Severe primary IGF-I deficiency (SPIGFD). Part 2

Short stature: Key challenges in diagnosis and management. Part 1

Gene therapy and gene-modified cell therapy in rare diseases

Neuroendocrine tumours: The role of SSA at progression - To continue or not?

Rare bone disease: Highlights from ASBMR 2022 - Part 3

Rare bone disease: Highlights from ASBMR 2022 - Part 2

Rare bone disease: Highlights from ASBMR 2022 - Part 1

Primary Biliary Cholangitis (PBC): Highlights from ILC 2022. Part 2

Primary Biliary Cholangitis (PBC): Highlights from ILC 2022. Part 1

Rare bone disease: Highlights from ASBMR 2021. Part 4

Rare bone disease: Highlights from ASBMR 2021. Part 2

Rare bone disease: Highlights from ASBMR 2021. Part 1

Primary Biliary Cholangitis (PBC): Highlights from EASL 2023 - Part 2